Rapid and sustained molecular response to nilotinib in a patient with sub-optimal response to imatinib

Rapid and sustained molecular response to nilotinib in a patient with sub-optimal response to imatinib

Authors

  • Mario Annunziata Divisione di Ematologia con Trapianto, AO Cardarelli, Napoli

DOI:

https://doi.org/10.7175/cmi.v5i3S.1122

Keywords:

Chronic myeloid leukemia, Imatinib, Nilotinib, Sub-optimal response, Early switch

Abstract

We describe here the case of a 40-years-old woman diagnosed as having chronic phase chronic myeloid leukemia and treated with standard dose of imatinib; the patient obtained the complete cytogenetic remission in 7 months, but she failed to achieve major molecular response (MMolR) after more than18 months of imatinib therapy. Sub-optimal response, defined according European LeukemiaNet guidelines, persisted despite of increasing imatinib dose to 600 mg daily. No BCR-ABL mutations were detected. Three months after switching to nilotinib 800 mg bid, the patient obtained MMolR. She experienced any toxicities due to nilotinib. We speculate about use of nilotinib in patients classified as sub-optimal at 18 months from imatinib.

Downloads

Published

2015-10-13

Issue

Vol. 5 No. 3S (2011)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)